magAssist Shortlisted for 2025 Prix Galien USA Best Start-Up Award

The Galien Foundation has announced the nominees for the 2025 Prix Galien USA Awards. magAssist has been nominated in the "Best Start-Up" category for its work in the development of ventricular assist devices and life support technologies. The award recognizes scientific innovations designed to improve human health.

An Internationally Recognized Award in Life Sciences

Established in 1970 and named after Galen, a pioneer in medicine, the Prix Galien was created to recognize innovation in the medical field. It is often referred to as the "Nobel Prize of the biomedical industry."

Since its U.S. introduction in 2007, the Prix Galien USA has been judged by a committee of Nobel laureates and other medical experts. Nominees are evaluated based on criteria that include scientific innovation, clinical value, and patient benefit, independent of commercial data. Past recipients of the award include Novartis for its CAR-T therapy, Kymriah®, and Abbott for its mitral valve repair device, Mitraclip®.

"The progress made in the life sciences over the past year has been notable," said Bruno Cohen, Chairman of The Galien Foundation. "These nominated projects demonstrate an accelerating trend in medical innovation."

Overview of the 2025 Nominations

The 2025 Prix Galien USA includes four categories: Best Digital Health Solution, Best Medical Technology, Incubator/Accelerator & Equity, and Best Start-Up. Nominees include companies such as Abbott, Empatica, Recursion, and Oura.

In the "Best Start-Up" category, 53 companies have been nominated from fields including AI-assisted diagnostics, medical devices, cell and gene therapies, and wearable monitoring.

magAssist Technology and Clinical Applications

magAssist Technology and Clinical Applications

• MoyoAssist® Extracorporeal VAD: This device is used in multiple tertiary hospitals to provide circulatory support for patients during high-risk PCI, treatment for acute heart failure, and complex cardiovascular surgeries. It is designed to maintain hemodynamic stability and can serve as a bridge to organ transplantation or cardiac function recovery

• NyokAssist® Percutaneous VAD: A collapsible, minimally invasive device intended for short-term cardiac support. It has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

• BreathMo® Portable ECMO System: This is a fully magnetically levitated extracorporeal membrane oxygenation (ECMO) system. The design aims to improve hemocompatibility and has indications for both extracorporeal ventricular assistance and extracorporeal membrane oxygenation.

  
  

Nomination and Outlook

The nomination for the 2025 Prix Galien USA places magAssist's technology alongside other developments recognized by the awards committee.

The 2025 Prix Galien USA Awards ceremony will be held on October 30 at the American Museum of Natural History in New York City.

magAssist will continue its research and development of ventricular assist devices and life support platforms, with the goal of providing additional treatment options for critically ill patients.